Orthovita, Inc. Announces Presentation of Clinical Results Evaluating Vitagel(TM) Surgical Hemostat in Reducing Blood Loss During Primary Unilateral Total Knee Arthroplasty

MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, is pleased to announce that Michael Bloomfield, M.D., of Cleveland Clinic, presented results of a study entitled “Prospective Randomized Evaluation of a Collagen/Thrombin and Autologous Platelet Hemostatic Agent During Total Knee Arthroplasty” on Friday, April 8, at the 29th Annual Meeting of the Mid-America Orthopaedic Association in Tucson, Arizona. Wael Barsoum, M.D. and Alison Klika, M.S. of the Cleveland Clinic, Cleveland OH, served as the principal investigators of the study.
MORE ON THIS TOPIC